摘要
化疗在减少肿瘤负荷、延长生存期等方面均具有重要作用。同时其不可忽视的细胞毒作用和对生活质量的降低也成为了限制其应用的重要原因。多年临床实践表明,中医肿瘤学与现代医学结合,取长补短,进一步提高了肿瘤防治的临床疗效。文章通过检索国内外相关文献,针对中医药联合化疗治疗晚期非小细胞肺癌增效相关研究、减毒相关研究两方面进行综合分析。结果显示中医药联合化疗能够:(1)提高对化疗的耐受性,增加化疗完成率和治疗依从性;(2)增加化疗远期疗效和瘤体稳定率;(3)对症减轻化疗引起的毒副反应及并发症,其中以骨髓抑制(白细胞、粒细胞减少)、消化道反应(恶心、呕吐、腹泻)改善最为明显;(4)提高患者整体生活质量。中医药联合化疗治疗晚期非小细胞肺癌显示了良好的增效减毒效果,但晚期范畴划分不明确,疗效多局限单一化疗方案而非整体化疗阶段,试验样本量整体偏小,评价手段代表性不足和缺乏相关因素分析均是目前研究仍存在的问题。
Chemotherapy plays an important role in reducing tumor load and prolonging survival, but it is still not satisfactory. At the same time, its non-negligible cytotoxic effect and the reduction of quality of life have become important reasons for limiting its application. Years of clinical practice have shown that the combination of TCM and modern medicine can make up for the shortcoming and further improve the clinical efficacy of tumor prevention and treatment. In this paper, by researching for relevant literature both at home and abroad, the authors comprehensively analysed two relevant aspects, synergism and attenuation, of TCM combination chemotherapy on the treatment of advanced NSCLC. The results show that TCM combined chemotherapy had the following functions. First, it increased tolerance to chemotherapy, the completion rate of chemotherapy and treatment compliance. Second, it increased the long-term efficacy of chemotherapy and the rate of tumor stabilization. Third, the therapy alleviated the adverse reactions and complications caused by chemotherapy, especially myelosuppression and gastrointestinal reaction（Myelosuppression appears as leukocyte and granulocyte decrease, and gastrointestinal reaction appeares as nausea, vomiting and diarrhea）. Forth, the therapy improved the overall quality of life of patients. TCM combination chemotherapy on the treatment of advanced NSCLC has good synergism and attenuation function. But the advanced stage category is unclear. The curative effects are mostly restricted to single chemotherapy regimen but not overall chemotherapy stage. And the test sample amount is small, the evaluation method is not representative and relative factors analysis is deficient. These problems are all impact the current research.
作者
郑佳彬
袁嘉萌
刘益华
李冰雪
林洪生
ZHENG Jia-bin;YUAN Jia-meng;LIU Yi-hua;LI Bing-xue;LIN Hong-sheng(Department of Oncology,Gnang＇anmen Hospital,China Academy of Chinese Medical Sciences,Beijing 100053,China)
出处
《中华中医药杂志》
CAS
CSCD
北大核心
2018年第11期5026-5030,共5页
China Journal of Traditional Chinese Medicine and Pharmacy
基金
中医药行业科研专项(No.201307006)
国家国际科技合作专项(No.2013DFA325)~~
关键词
非小细胞肺癌
晚期
化疗
增效
减毒
生活质量
Non-small cell lung cancer （NSCLC）
Advanced stage
Chemotherapy
Synergism
Attenuation
Overall quality of life
